[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.157.73. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
December 1987

Immunotherapy of Pulmonary Metastases Using Monoclonal Antibody to T-Cell Suppressor Factor and Interleukin 2

Author Affiliations

From the Department of Surgery, Cleveland Metropolitan General Hospital and Case Western Reserve University School of Medicine, Cleveland (Drs Kim and Imbembo and Ms Warnaka); and the Medical Biology Institute, La Jolla, Calif (Dr Iverson).

Arch Surg. 1987;122(12):1455-1459. doi:10.1001/archsurg.1987.01400240103019
Abstract

• Tumor-induced immune suppression of the host may pose a barrier to successful immunotherapy. A monoclonal antibody (MAb 14-12) able to bind and inhibit murine soluble T-cell suppressor factor was tested for in vivo antitumor activity by treatment of mice bearing three-day established pulmonary metastases of a weakly immunogenic methylcholanthreneinduced fibrosarcoma (MCA 106). Administration intraperitoneally in combination with interleukin 2 (IL-2), a growth factor for activated T lymphocytes, resulted in a significant reduction (60% to 90%) of metastases. Neither IL-2 nor monoclonal antibody alone had significant antitumor effects. This study demonstrates in vivo potentiation of IL-2 antitumor activity with an anti—T-cell suppressor factor and points to possible strategies for clinical application.

(Arch Surg 1987;122:1455-1459)

×